London:
Results from the first swine-flu vaccine trials taking place in Britain have revealed a strong
immune response after administering just one dose.
The pilot study, run by the University of Leicester and Leicester Hospitals, was trialed with 100 healthy volunteers, aged between 18 and 50.
Dr Iain Stephenson, who led the trial at the Leicester Royal Infirmary, said: "The clinical trial of Novartis MF59-adjuvanted cell-based A (H1N1) vaccine indicates that the 'swine flu' vaccine elicits a strong immune response and is well-tolerated.
"Results showed that the serum antibody responses were highest among subjects who received two doses of vaccine, however a single vaccine dose also induced responses associated with protection against influenza.
"The findings showed that it is possible to induce protective antibody against A (H1N1) infection within two weeks of administration of a single low-dose adjuvanted vaccine".
The trial evaluated the tolerability and immunogenicity of the vaccine, and tested different schedules of vaccination, in terms of time between vaccinations.
The vaccine schedule was one or two doses of 7.5 microgram MF-59 adjuvanted surface-antigen A/California/2009 vaccine derived from cell-culture.
immune response after administering just one dose.
The pilot study, run by the University of Leicester and Leicester Hospitals, was trialed with 100 healthy volunteers, aged between 18 and 50.
Dr Iain Stephenson, who led the trial at the Leicester Royal Infirmary, said: "The clinical trial of Novartis MF59-adjuvanted cell-based A (H1N1) vaccine indicates that the 'swine flu' vaccine elicits a strong immune response and is well-tolerated.
"Results showed that the serum antibody responses were highest among subjects who received two doses of vaccine, however a single vaccine dose also induced responses associated with protection against influenza.
"The findings showed that it is possible to induce protective antibody against A (H1N1) infection within two weeks of administration of a single low-dose adjuvanted vaccine".
The trial evaluated the tolerability and immunogenicity of the vaccine, and tested different schedules of vaccination, in terms of time between vaccinations.
The vaccine schedule was one or two doses of 7.5 microgram MF-59 adjuvanted surface-antigen A/California/2009 vaccine derived from cell-culture.
